Baicheng Pharmaceutical: The oral solution BIOS2242 developed by its wholly-owned subsidiary has obtained the clinical trial approval notification.

Baicheng Pharmaceutical announced that its wholly-owned subsidiary, Smile Pharmaceutical, has obtained the Clinical Trial Approval Notification from the National Medical Products Administration for the drug BIOS2242 oral liquid. BIOS2242 oral liquid is used for the treatment of mild to moderate acute ischemic stroke.